Journal of Hepatocellular Carcinoma (Aug 2023)

Prognosis of Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization(MC-hccAI 001): Development and Validation of the ALFP Score

  • Gong B,
  • Wang X,
  • Guo W,
  • Yang H,
  • Shi Y,
  • Chen Y,
  • Gao S,
  • Chen J,
  • Liu L,
  • Lu L,
  • Chen X

Journal volume & issue
Vol. Volume 10
pp. 1341 – 1351

Abstract

Read online

Baocuo Gong,1,2,* Xuewen Wang,1,3,* Wanting Guo,1 Hongyi Yang,1 Yanhong Shi,1 Yaying Chen,1 Simiao Gao,1 Jialin Chen,1 Lifang Liu,2 Linbin Lu,1 Xiong Chen1 On behalf of Fujian HCC-biomarker Study Group1Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, 350025, People’s Republic of China; 2Department of Oncology, Oriental Hospital Affiliated to Xiamen University, Fuzhou, Fujian, 350025, People’s Republic of China; 3Department of Histology and Embryology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350122, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linbin Lu; Xiong Chen, Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, 321 Xihong Road, Fuzhou, Fujian, 350025, People’s Republic of China, Email [email protected]; [email protected]: Transarterial chemoembolization (TACE) is the recommended first-line treatment for intermediate-stage Hepatocellular carcinoma (HCC) patients. However, predicting the survival of HCC patients receiving TACE remains challenging.Methods: In this retrospective study, we analyzed a total of 1805 HCC patients who received TACE. The patients were randomly divided into a training set (n = 1264) and a validation set (n = 541). We examined various prognostic factors within the training set and developed a simple ALFP (ALBI grade, AFP, and Prothrombin time) score, which was subsequently validated using the independent validation set.Results: Our multivariate analysis revealed that baseline ALBI grade 2 or 3, AFP ≥ 100 ng/mL, and PT > 13.1 s were independent unfavorable prognostic factors for HCC patients receiving TACE (p 13.1 s. The score has a range of 0 to 3, and higher scores are associated with poorer outcomes. The median overall survival (OS) varied significantly among different ALFP score groups, both in the training set and the validation set (p

Keywords